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ABSTRACT
The enzyme 5a-reductase plays a key role on several brain func-
tions controlling the formation of anxiolytic/anesthetic steroids de-
rived from progesterone and deoxycorticosterone, the conversion of
testosterone to dihydrotestosterone, and the removal of excess of
potentially neurotoxic steroids. Two 5a-reductase isoforms have been
cloned: 5a-reductase type 1 is widely distributed in the body, and
5a-reductase type 2 is confined to androgen-dependent structures. In
this study, the gene expression of the two 5a-reductase isozymes has
been analyzed in fetal, postnatal, and adult rat brains by RT-PCR
followed by Southern analysis. 5a-Reductase type 1 messenger RNA
is always detectable in the rat brain [from gestational day 14 (GD14)
to adulthood]. 5a-Reductase type 2 messenger RNA expression is
undetectable on GD14, increases after GD18, peaks on postnatal day
2, then decreases gradually, becoming low in adulthood. This pattern
of expression appears to be correlated with the rate of production of
testosterone by the testis. The possible control by androgens of gene
expression of the two isozymes has been studied in brain tissues of
animals exposed in utero to the androgen antagonist flutamide; the
sex of the animals was determined by genetic sex screening of the SRY
gene located on the Y-chromosome. In the brain of male embryos,
flutamide treatment inhibited the expression of 5a-reductase type 2;
this effect was much less pronounced in females. Moreover, 5a-
reductase type 2 gene expression in cultured hypothalamic neurons
is highly induced by testosterone and by the phorbol ester 12-O-
tetradecanoyl-phorbol-13 acetate. The transient, androgen-regu-
lated, expression of 5a-reductase type 2 overlaps the critical period of
development, which may be important for sexual differentiation of the
brain and for the formation of anxiolytic/anesthetic steroids involved
in the stress responses associated with parturition. (Endocrinology
139: 2171–2178, 1998)
IN MAMMALS, gonadal steroids play an essential role inthe process of brain differentiation, especially during
embryonic development and in early postnatal life. In par-
ticular, testosterone is responsible for the sexual differenti-
ation of the male brain; this includes the organization of both
endocrine and behavioral functions, for instance, the dimor-
phic regulation of gonadotropin and GH secretion, the con-
trol of sexual and aggressive behavior, etc. This process is
thought to be largely mediated by the formation of estrogens
by the enzyme aromatase (for review, see Refs. 1 and 2).
Dihydrotestosterone (DHT), which is formed in the brain via
the 5a-reduction of testosterone, has also been shown to exert
specific organizational roles on selected neuronal popula-
tions (3–5) and, therefore, is possibly involved in the pro-
cesses of sexual differentiation of some brain regions.
The physiological importance of 5a-reductase (5a-R) in the
brain resides also in its capability to convert progesterone
and the corticoids to their respective 5a-reduced derivatives,
providing the substrates for the 3a-hydroxysteroid dehy-
drogenase, the enzyme responsible for the formation of
3a-hydroxy-5a-pregnan-20-one (allopregnanolone or tetra-
hydroprogesterone) and of 3a,21-dihydroxy-5a-pregnan-20-
one (tetrahydrodeoxycorticosterone), which are two potent
neurally active steroids. These two 5a-reduced and 3a-
hydroxylated compounds are unable to interact with the
classical intracellular receptors for progesterone and the glu-
cocorticoids, and their actions are mediated by the g-ami-
nobutyric acidA receptor (6). The activation of this receptor
may explain their potent anesthetic/anxiolytic activities.
5a-R, then, appears to be a key regulatory enzyme that
controls several distinct brain functions; moreover, in coop-
eration with other enzymatic systems, it may contribute to
the catabolism of potentially neurotoxic steroids (e.g. the
glucocorticoids, which, when present in excess, might induce
apoptotic processes in selected neuronal populations of the
hippocampus) (7, 8).
Two isoforms of the enzyme 5a-R have been cloned; they
catalyze the same reaction, but possess different biochemical
and pharmacological properties, distinct cell- and tissue-
specific patterns of expression (9, 10), and different subcel-
lular distributions (11, 12). Therefore, the two isozymes may
play distinct physiological functions. This hypothesis is sup-
ported by the observation that although the type 1 isoform
is widely expressed in various tissues (with the highest levels
in the liver), the type 2 isoform appears to be selectively
concentrated in classical androgen-dependent structures,
such as prostate, seminal vesicles, etc. (13).
Considerable 5a-R activity has been measured in the cen-
tral nervous system (CNS) of several mammalian species (14,
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15). The enzymatic activity is more pronounced in brain
regions such as the hypothalamus, the midbrain, and all
structures rich in white matter; this phenomenon is due to the
peculiar localization of elevated levels of 5a-R activity in
myelin (14). The type 1 isoform of 5a-R appears to be re-
sponsible for the activity in myelin, because the kinetic con-
stants of the enzyme present in the purified myelin are very
similar to those found in the recombinant type 1 isozyme
(15–18); moreover, a polyclonal antibody raised against the
5a-R type 1 recognizes the enzymatic protein in the myelin
sheaths of the axons of rat optic chiasm (18).
Few data are available on the presence and distribution of
the two 5a-R isoforms in the rat brain, the developmental
patterns of expression, or the possible control mechanisms
exerted by hormonal steroids. Specific messenger RNAs
(mRNAs) coding for the type 1 isoform (13, 19, 20) have been
detected on total RNAs obtained from the whole brain of
7-week-old male rats. The presence of 5a-R type 2 mRNA is
still controversial (13, 20). A recent study performed in this
laboratory (19) has shown the presence of type 1, but not 5a-R
type 2, mRNA in cultured rat brain cells, with maximal levels
of expression in neurons. However, cultured cells may not
represent the physiological situation occurring in vivo, be-
cause of the absence of paracrine, endocrine, and/or neu-
ronal regulations.
The aim of the present study was to evaluate, using the
RT-PCR technique, the expression of the two isoforms of the
5a-R in rat brain at different stages of development and to
clarify whether their expression might be influenced by an-
drogens. This aspect has been studied both in vivo, by the in
utero exposure to the androgen receptor (AR) antagonist
flutamide, and in vitro on cultured fetal hypothalamic neu-
rons. The brains of male and female fetuses, identified by
genetic screening of a marker gene (SRY) of the Y-chromo-
some, have been separately studied in the experiments with
flutamide.
Materials and Methods
Materials
Oligonucleotide sequences: All the synthetic oligonucleotides were
obtained from Pharmacia Biotech (Uppsala, Sweden). The following
materials were also used: DMEM, Dulbecco’s PBS, and trypsin (Bio-
chrom, Berlin, Germany); heat-inactivated FCS (Life Technologies,
Grand Island, NY); penicillin, streptomycin, bovine insulin, bovine
transferrin, putrescine, sodium selenite, phenol red-free DMEM, dia-
minobenzidine tetrahydrochloride, steroids, Harris hematoxylin, and
chemicals (Sigma Chemical Co., St. Louis, MO); GeneAmp kit (Perkin-
Elmer, Palo Alto, CA); and Zeta-Probe (Bio-Rad, Richmond, CA).
Animals
To perform the ontogenetic studies, brains were obtained from rat
embryos on gestational days (GD) 14, 16, and 18; on postnatal days (PN)
2, 7, 10, 14, 18, 22, and 28; and in adulthood. The animals were obtained
from timed pregnant Sprague-Dawley rats (Charles River, Calco, Italy)
that were maintained in animal quarters with controlled temperature
and humidity. The light schedule was 14 h light and 10 h dark (lights
on at 0630 h). The mothers were fed a standard pellet diet and water was
provided ad libitum. In the experiments performed to evaluate the role
of androgens on 5a-R expression, flutamide was injected daily at a dose
of 100 mg/kg to timed pregnant rats from GD14 to GD21. The embryos
were obtained by surgical procedure on GD21, the presumed day of
birth.
Cell cultures
Hypothalamic neuronal cell cultures were obtained from the hypo-
thalamic region of the brain of 16-day-old embryos by disrupting the
tissue in phenol red-free DMEM containing 20% FCS. The cell suspen-
sion was then plated for 1 h in 10-mm petri dishes to remove fibroblasts
(which rapidly adhere to the plate), and floating neurons were collected
and plated on polylysine-coated 35-mm petri dishes in phenol red-free
DMEM containing 20% FCS. After 24 h, the medium was replaced with
phenol red-free DMEM containing 50 U/ml penicillin, 50 U/ml strep-
tomycin, 5 mg/ml bovine insulin, 100 mg/ml bovine transferrin, 100 mm
putrescine, and 20 nm sodium selenite until the collection of cells (5 days
in vitro).
Immunocytochemistry
The immunocytochemical characterization of hypothalamic neuronal
cultures was performed using a rabbit polyclonal antibody raised
against the neuron-specific enolase (Dako Corp., Milano, Italy). The
neuronal cell layer was fixed in 4% paraformaldehyde for 5 min at room
temperature. The cells were washed with 0.1% Triton X-100 in phosphate
buffer (0.01 m) for 20 min and then incubated with 1.5% normal goat
serum for 20 min to block nonspecific binding of the biotinylated sec-
ondary antibody. The antibody was applied to the cells at a dilution of
1:10 for 1 h at room temperature. The cells were then washed with 0.1%
Triton X-100 in phosphate buffer (0.01 m) for 20 min, incubated with the
biotinylated secondary antibody (1:200 dilution; rabbit antirat IgG; Vec-
tor Laboratories, Burlingame, CA) for 30 min, then washed three times
with 0.1% Triton X-100 in phosphate buffer (0.01 m) for 3 min each time,
and incubated with peroxidase-avidin for 30 min. After three washes
with 0.1% Triton X-100 in phosphate buffer (0.01 m) for 3 min each time,
the cells were finally exposed to the substrate solution (1.6 mg/ml urea
hydrogen peroxide and 0.7 mg/ml 3,39-diaminobenzidine tetrahydro-
chloride) for 5 min, washed three times with 0.1% Triton X-100 in
phosphate buffer (0.01 m) for 3 min each time, stained with Harris
hematoxylin, and observed under a light microscope.
RT-PCR
The brain tissues or the cultured hypothalamic neurons were solu-
bilized in guanidium isothiocyanate, and total RNA was prepared by
centrifugation over a 5.7-m cesium chloride step cushion as previously
described (19). In the experiments requiring genetic sex screening, total
genomic DNA was recovered from the intermediate layer of the cesium
chloride step cushion of each tube using a sterile syringe, precipitated
with isopropanol, washed with 70% ethanol, and then resuspended in
sterile water.
RT-PCR was performed using a GeneAmp kit with 2 mg total RNA
from each sample. The same extracts of total RNA were subjected to
specific analysis for the presence of 5a-R type 1 and type 2 mRNA.
Samples of total RNA obtained from adult rat prostate, known to contain
high levels of mRNAs of the two isozymes, were used as positive
controls (10). The synthetic oligonucleotides used as primers are sche-
matically reported in Fig. 1, and the nucleotide sequences were the
following: for 5a-R type 1 amplification: upstream primer, 59-CGA CCT
GCC TGG TTC ATA CA; downstream primer, 59-GGT CAC CCA GTC
TTC AGC AT; and for 5a-R type 2 amplification: upstream primer,
59-GTC CTG CTG GCT CTC TTC TC; downstream primer, 59-CAG GCT
TCC TGA GCT GGC GC. Nonspecific genomic DNA amplification is
avoided in the two types of analyses performed because the sets of
primers chosen are located on different exons of each gene (as deter-
mined by comparison of the rat and human sequences alignments).
Moreover, the RNA preparations were assayed in preliminary experi-
ments in which RT-PCR was performed, omitting the addition of reverse
transcriptase to the samples. No specific bands were observed, indicat-
ing that genomic DNA could not be amplified.
The RT conditions were 42 C for 45 min followed by 5 min at 95 C,
using a final concentration of 1 mm of each deoxy-NTP, 1 U ribonuclease
inhibitor, 2.5 U murine leukemia virus reverse transcriptase, and the
downstream primer in a final volume of 20 ml. The same buffer (50 mm
KCl, 10 mm Tris-HCl, and 2 mm MgCl2) was used for both transcription
and amplification. The PCR reaction was performed using the ampli-
fication mixture comprised of 2.5 U Ampli-Taq polymerase and the
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upstream primer in a final volume of 100 ml. Samples were amplified by
35 repeated cycles as follows: 95 C for 1 min, 42 C for 1 min, and 72 C
for 1 min.
The genetic sex-screening determination, performed on genomic
DNA by amplification of the SRY gene located on the Y-chromosome,
was obtained using the following primers: upstream primer, 59-TAC
AGC CTG AGG ACA TAT TA; and downstream primer, 59-GCA CTT
TAA CCC TTC GAT GA. The PCR conditions are the same as those
described for 5a-R type 1 and type 2 analysis.
The amplification products were separated by electrophoresis on 2%
agarose gel and identified by ethidium bromide staining. The amplified
complementary DNAs (cDNAs) were transferred to blotting nylon
membrane (Zeta-Probe) by capillary elution in 10 3 SSC (standard saline
citrate) and fixed by baking at 80 C for 2 h under vacuum. Southern
analysis was performed using the following synthetic oligonucleotides
as radiolabeled probes: 5a-R type 1 oligoprobe, 59-AGC AGA TAC TTG
AGC CA; and 5a-R type 2 oligoprobe, 59-ACA TTA CTT CCA CAG GAC
ATT T. The labeling reactions were performed on the free 59-end of the
oligoprimers using T4 DNA polynucleotide kinase, and [g-32P]deoxy-
ATP. The cDNA on the membrane was then incubated at 45 C for 4 h
with the prehybridizing solution, added to the 59-end 32P-labeled oli-
gonucleotide probes (1 3 106 cpm/ml) specific for the two isoforms of
the 5a-R cDNAs, and hybridized at 45 C overnight. After washing, the
membranes were exposed to x-ray films.
RT-PCR blanks were performed using distilled water and simulta-
neously subjected to RT-PCR/Southern blotting with the same reagents
and conditions as those described above; in none of the experiments
performed could a specific signal be obtained, indicating that no con-
tamination of reagents occurred in these studies.
Results
Gene expression of the two 5a-R isoforms in the rat brain
was analyzed using RT-PCR combined with Southern
analysis
Figure 1 schematically shows the synthetic primers and
oligoprobes selected for RT-PCR analysis of 5a-R type 1 and
type 2 gene expression in the rat brain. The nucleotide se-
quences have been deduced from the published cDNA of the
two isozymes and are expected to produce two fragments of
approximately the same size. Simultaneous RT-PCR ampli-
fications of 5a-R type 1 and type 2 mRNAs were always
performed, using the same RNA preparations with a great
excess of oligoprimers; the amplification products were then
employed in distinct Southern analyses using 32P-labeled
oligoprobes. Using this procedure, a semiquantitative anal-
ysis was made possible by evaluating the ratio of the mean
optic density (MOD) of the radioactive spots obtained for
each of the two 5a-R isoforms after Southern analysis (see
below).
Ontogenetic studies on the whole rat brain
The first set of experiments was performed to investigate
gene expression of the two types of 5a-R in the brain of rats
in late fetal/early postnatal life, a crucial period for sexual
differentiation toward the male pattern of the rat CNS. The
brains of rat embryos at different gestational days (GD14, -16,
and -18); those of male rats taken from PN2 to PN28; and
those from adult male rats were considered in this study. The
Southern analysis performed on the RT-PCR products of
amplification obtained using the set of primers specific for
5a-R type 1 is shown in Fig. 2A. Specific amplification prod-
ucts of the expected size (287 bp) were detectable in the rat
anterior prostate (used as positive control) and in all brain
samples examined. The expression pattern of this isozyme
appeared essentially constant throughout the different time
intervals considered. The only exception was a small increase
in the signal intensity around the time of birth (GD18).
When gene expression of 5a-R type 2 was analyzed in the
same brain samples, a totally different pattern of expression
was observed (Fig. 2B). No detectable amplification products
(279 bp) of the 5a-R type 2 gene were observed at the earliest
stages of fetal brain development (GD14 and GD16), whereas
a large increase in gene expression of type 2 mRNA was
present in the brains of embryos in the late stages of fetal
development (GD18) and in early postnatal life (with an
apparent maximum on PN2). After birth, the gene expression
of this isozyme gradually decreased, becoming relatively low
FIG. 1. Location on the 5a-reductase
isoform cDNAs of the oligoprimers and
oligoprobes used in the RT-PCR analy-
ses of 5a-R type 1 and type 2 gene ex-
pression in the rat brain. The nucleotide
sequences have been deduced from the
published cDNA of the two isoforms and
are expected to produce two fragments
of about 300 bp; the selection was made
in a portion of cDNA nonconserved in
the two isoforms and with a limited de-
gree of homology with other published
sequences. The primers are expected to
be located on different exons of each
gene (as determined by comparison of
the rat and human sequence align-
ments); this has been confirmed by the
absence of amplified products in PCR
analysis performed on genomic DNA (or
total RNA), assayed by omitting the re-
verse transcriptase enzyme in the sam-
ples.
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after the second week of life and almost disappearing in
adulthood. Even if the absolute values of expression of the
two isoforms of 5a-R in the brain cannot be determined using
RT-PCR, a semiquantitative analysis of the relative expres-
sion of the two isozymes was attempted, and the results are
shown in Fig. 2C. To this purpose, the MOD values of the
radioactive spots obtained on the x-ray films after Southern
analysis of 5a-R type 2 mRNA were measured, and these
values were normalized with those of 5a-R type 1 measured
in the same way in the corresponding samples. It appears
that the highest ratio of type 2/type 1 was present during the
perinatal period, and this dramatically fell at the beginning
of the second week of life. The pattern of expression of the
5a-R type 2 gene appears to be correlated with the level of
testosterone produced by the fetal testis, which begins on
GD14 and is maximal around the time of birth (21, 22); this
suggests a possible involvement of androgens in the control
of 5a-R type 2 biosynthesis.
FIG. 2. Ontogenetic expression of 5a-R
type 1 and type 2 genes in rat brain. The
brains of rat embryos on GD14, 16, and
18; those of newborn male rats taken on
PN2, 7, 10, 14, 18, 22, and 28; and those
from adult male rats were considered.
Total RNA from the rat ventral pros-
tate, a structure known to express both
5a-R isoforms, was used as a positive
control. Contemporary RT-PCR ampli-
fication of type 1 and type 2 mRNA was
performed using the same RNA prepa-
rations in the presence of a great excess
of oligoprimers; the amplification prod-
ucts were then used in distinct South-
ern analysis with 32P-labeled oligo-
probes. The figure is representative of
the data obtained from a single exper-
iment. A, RT-PCR/Southern analysis
obtained using the set of primers selec-
tive for 5a-R type 1; the specific ampli-
fication products appeared at the ex-
pected size (287 bp). B, Analysis
performed using the set of primers spe-
cific for 5a-R type 2 on the same sam-
ples reported in A. C, Semiquantitative
analysis of the relative expressions of
the two isozymes; the plot was obtained
by measuring the MOD after SA at the
different intervals considered in the
analysis described in A and B; the re-
sults obtained for 5a-R type 2 analysis
were normalized with the values ob-
tained for 5a-R type 1 in the correspond-
ing samples.
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Androgen regulation of 5a-R type 2 gene expression
To verify the hypothesis that endogenous androgens
might induce 5a-R type 2 gene expression in the rat brain
during the perinatal period, the AR antagonist flutamide was
given to pregnant female rats (at daily doses of 100 mg/kg
in sesame oil, from GD14 to birth) to counteract the action of
testosterone secreted from the testes of male embryos (which
normally begins on GD14). Flutamide is known to cross the
placental and blood-brain barriers. The experiments were
performed using brains at a point when the expression of
5a-R type 2 is maximal, i.e. the time of birth (see above). To
this purpose, the embryos were surgically removed on the
day of presumed birth (21th day in timed pregnant females)
to avoid possible delays of delivery consequent to flutamide
treatment. As flutamide treatment also blocks the differen-
tiation of secondary reproductive structures, males and fe-
males were completely indistinguishable; consequently, a
genetic screening of the sex of the embryos was performed.
In particular, the presence of the sex-determining gene SRY
(An, J., N. Beauchemin, J. Albanese, and A. K. Sullivan,
unpublished results; GenBank accession no. X89730), which
is located on the Y-chromosome, was analyzed using PCR.
Male rats should give specific amplification products of
about 300 bp, clearly identifiable by ethidium bromide stain-
ing (see Fig. 3, lower panel). Figure 3 shows the results of the
RT-PCR/Southern analysis performed on the total RNA ex-
tracted from the brains of rats exposed in utero to flutamide
compared with that in brains from unexposed rats. 5a-R type
1 gene expression was very similar in the brains of male and
female rats obtained from control and flutamide-treated
mothers (Fig. 3, upper panels). No sex differences were present
in the expression of the type 2 gene between control male and
female brains (Fig. 3, middle panels). The antiandrogen flut-
amide significantly decreased the levels of mRNA for 5a-R
type 2 in the male rat brain, bringing most of the samples to
undetectable levels. Flutamide only slightly diminished the
expression of type 2 isoform mRNA in the female brains.
Figure 4 shows a semiquantitative analysis on the relative
expressions of the two 5a-R isoforms in the brain of newborn
animals, exposed in utero to flutamide. A significant decrease
in the levels of 5a-R type 2 was evident in the brains of male
rats when the MOD (left panel) or the 5a-R type 2/5a-R type
1 MOD ratio (right panel) was considered. On the contrary, no
significant variations were detectable in females.
Control of 5a-R gene expression in hypothalamic neurons
To further clarify the role of androgens in the control of the
gene expression of 5a-R type 2, a second approach was used.
Cultures of rat fetal hypothalamic neurons obtained from the
brain of embryos on GD16 were prepared for these experi-
ments. The hypothalamic neurons were selected because this
brain region is one of the primary target structures of an-
drogen action. Immunocytochemical characterization of the
cultured hypothalamic cells has been initially performed us-
ing a specific monoclonal antibody raised against the neuron-
specific enolase. Figure 5 shows that the cultures were mainly
composed of neuron-specific enolase-positive cells, possess-
ing a neuronal cell phenotype. These cell preparations were
previously shown to express only 5a-R type 1 (19) and con-
sequently were suitable to study a possible induction by
testosterone of 5a-R type 2 gene expression. In addition, to
verify whether other activators (i.e. growth factors, neuro-
transmitters, neurohormones, etc.), interacting at the cell sur-
face and stimulating membrane receptors, might participate
in the control of 5a-R genes, the effect of 12-O-tetradecanoyl-
FIG. 3. Effect of in utero flutamide exposure on 5a-R type 1 and type 2 gene expression in the rat brain. To assess whether endogenous androgens
control the induction of the expression of 5a-R type 2 in the rat brain during the perinatal period, timed pregnant female rats were treated
daily with the potent AR antagonist flutamide (at daily doses of 100 mg/kg in sesame oil, from GD14 until birth). The brains of animals were
removed on the days of maximal expression of 5a-R type 2, which occurs at the time of birth; therefore, the embryos were obtained by surgical
procedure on GD21, which is the presumed day of birth, to avoid possible delay of delivery related to flutamide treatment. A, RT-PCR/Southern
analysis of total RNA from male rat brains exposed in utero to flutamide compared with those obtained from unexposed rats. Upper panel,
Analysis of 5a-R type 1 gene expression; middle panel, analysis of 5a-R type 2 gene expression; lower panel, ethidium bromide staining for the
genetic screening of the sex of the embryos, performed by analyzing the presence of the sex-determining gene, SRY, a specific gene localized
on the Y-chromosome, by PCR on genomic DNA; male rats give a specific amplification product of about 300 bp. B, RT-PCR/Southern analysis
of total RNA from female rat brains exposed in utero to flutamide compared with those obtained from unexposed rats. Upper panel, Analysis
of 5a-R type 1 gene expression; middle panel, analysis of 5a-R type 2 gene expression; lower panel, ethidium bromide staining for genetic
screening of the sex of the embryos, performed by analyzing the presence of the sex-determining gene, SRY, a specific gene localized on the
Y-chromosome, by PCR on genomic DNA; female rats do not give specific amplification products of about 300 bp.
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phorbol-13 acetate (TPA), a potent activator of the protein
kinase C pathway, was analyzed.
Figure 6 shows the RT-PCR/Southern analysis per-
formed on cultured hypothalamic cells treated with tes-
tosterone (20 nm) or TPA (20 nm). No variation in expres-
sion levels was observed in the case of 5a-R type 1 mRNA.
On the contrary, type 2 mRNA was not detectable in un-
treated control cells, but appeared to be highly induced
after treatment with testosterone. Also, TPA efficiently
induced 5a-R type 2 mRNA expression in hypothalamic
neurons. In these cells, testosterone may act directly, after
conversion into DHT (a processes mediated by the 5a-Rs)
and/or into estrogens (formed via the aromatase enzy-
matic system); both metabolic pathways are present and
active in neurons (19). The involvement of the estrogen
receptor and estradiol as possible mediators of the action
of testosterone on the 5a-R type 2 gene in neurons can
probably be excluded, because 5a-R type 2 mRNA was not
detectable in neuronal cells cultured in the presence of
estrogens (19). Preliminary data obtained in our laboratory
indicate that DHT is able to mimic, but with a lower
potency, the testosterone-dependent induction of 5a-R
type 2 mRNA in cultured hypothalamic neurons.
Discussion
The data presented here have shown that the 5a-R type 1
enzyme is constitutively expressed in the rat CNS at all stages
of brain development, with a small increase around the time
of birth. This is reminiscent of the increased enzymatic ac-
tivity measured at neutral pH (optimal for type 1 isozyme)
(14) and the type 1 mRNA content that occurs in the rat
medial basal hypothalamus on GD18 (20). The expression of
5a-R type 1 is similar in males and females and does not
appear to be controlled by androgens or by activation of the
protein kinase C pathway.
The gene expression of 5a-R type 2 is totally different. This
isoform is transiently expressed in the rat brain in late fetal/
early postnatal life. The pattern of expression of 5a-R type 2
FIG. 4. Analysis of the relative expres-
sions of the two 5a-R isoforms in the
brains of newborn animals after expo-
sure in utero to flutamide. A, The aver-
age 6 SEM of the MOD for type 1 or type
2 5a-R gene expression detected by RT-
PCR/Southern analysis (and shown in
Fig. 3) was evaluated by computer anal-
ysis for control or flutamide-treated
male and female rats. B, Analysis of the
relative expressions of the two isozymes
obtained by measuring the MOD after
RT-PCR/Southern analysis performed
on the samples shown in Fig. 3; the ratio
was obtained on the basis of the values
shown in A; therefore, the results ob-
tained for 5a-R type 2 analysis were
normalized with the values obtained for
5a-R type 1 in the corresponding sam-
ples.
FIG. 5. Immunocytochemical analysis
of the hypothalamic neuronal cultures
using an antibody raised against the
neuron-specific enolase. Cell cultures
were obtained from the hypothalamic
area of rat embryos on GD16 and main-
tained as described in Materials and
Methods. Cells were fixed with 4% para-
formaldehyde and incubated with the
rabbit polyclonal antibody raised
against the neuron-specific enolase at a
dilution of 1:10 for 1 h at room temper-
ature. After washing, the cells were in-
cubated with the biotinylated second-
ary rabbit antirat antibody (1:200
dilution for 30 min at room tempera-
ture) and then with peroxidase-avidin
(for 30 min at room temperature). After
washes, the cells were exposed to the
substrate solution (1.6 mg/ml urea hy-
drogen peroxide and 0.7 mg/ml 3,39-dia-
minobenzidine tetrahydrochloride) for
5 min. The cells were then counter-
stained as described in Materials and
Methods and observed under a light mi-
croscope.
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overlaps the secretory profile of testosterone (21, 22), leading
us to hypothesize that this isoform could be modulated by
the increased levels of circulating androgens occurring in
male fetuses around the time of birth; this hypothesis is also
supported by the observation that AR (23) is elevated in rat
brain during late fetal/early postnatal life and is higher in
male than in female brains (23). The role of androgens in the
expression of 5a-R type 2 and the possible gender difference
were evaluated at the time of its maximal expression in
brains using male and female fetuses (identified by genetic
sex screening based on the presence of the Y-chromosome)
either untreated or exposed in utero to the AR antagonist
flutamide. In control animals, 5a-R type 2 mRNA levels are
similar in the brains of the two sexes. Flutamide treatment
produces a significant decrease in the levels of expression of
5a-R type 2 in male animals, whereas it is clearly less effective
in modulating the expression of this isoform in females.
These data are indicative of a differential mechanism of con-
trol of the type 2 isozyme in male and female rat brains.
Androgens may then represent the triggering element for the
expression of this isoform in males, whereas other control
mechanisms are probably involved in females (e.g. growth
factors, neurotransmitters, other steroids, etc.). The andro-
genic control of 5a-R type 2 gene in the brain has also been
confirmed using cultured hypothalamic neurons, but unfor-
tunately it was not possible in this study to separate male and
female hypothalamic neurons due to the extremely low re-
covery of cells per rat hypothalamus.
The data reported here underline the existence of selective
ontogenetic patterns of regulation by androgens of the two
genes in the brain and generally agree with the data obtained
in classic androgen-dependent structures of the urogenital
tract. In fact, in those structures, androgens induce 5a-R type
2 mRNA, but not 5a-R type 1 (24). This is peculiar for the
perinatal period, as it has been shown that in the prostate of
adult rats, both isozymes are controlled by androgens (13,
24).
Our in vitro results have also shown that 5a-R type 2 may
be induced by activation of the protein kinase C pathway;
therefore, not only androgens, but other factors may be of
importance in the control of the type 2 gene in the brain. The
level of complexity of such regulation requires further in-
vestigation, taking into consideration other intracellular sig-
naling pathways.
Together, these data suggest that 5a-R type 2 may be
involved in the control of brain sex differentiation occurring
during a very critical period, when androgen-organizing
effects are thought to take place in the CNS. In principle,
testosterone may exert its actions as such or after being me-
tabolized into estrogens or DHT. Although it is generally
accepted that the aromatization of testosterone into estrogens
is responsible for the sexual differentiation of the brain to-
ward the male pattern, DHT has been recently shown to be
essential for the development and organization of selected
neuronal populations. For instance, DHT has been shown to
induce, in the male rat, a decrease in the volume of the
sexually dimorphic nucleus of the accessory olfactory tract to
levels found in females (25). Conversely, the postnatal ad-
ministration of the antiandrogen cyproterone acetate to fe-
males produces an increment in the dimensions of this nu-
cleus to volumes not dissimilar from those found in control
males. Moreover, in male rats, DHT is needed, together with
estrogens, to achieve full masculine development of the sex-
ually dimorphic spinal nucleus of the bulbocavernosus (4). In
some amphibians, DHT is responsible for maintenance of the
sexual dimorphism of the pretrigeminal nucleus producing
vasotocin (26). DHT is detectable in relatively high concen-
trations in several regions of the rat brain, such as the amyg-
dala and the hypothalamus (27), which are also particularly
rich in AR (28). Testosterone and DHT modify the number
of branching points in cultured preoptic neurons (4, 5), acting
as morphogenetic signals for developing hypothalamic neu-
rons containing the aromatase. Finally, androgens may in-
fluence the plasticity and the synaptic connectivity of hypo-
thalamic aromatase-positive neurons (29); these effects are
AR mediated, because they are suppressed by the antian-
drogen flutamide, but not by the antiestrogen tamoxifen (29).
These observations suggest that androgens, at least in these
structures, may act through DHT activation of AR. It is the
authors’ opinion that the role of DHT in brain differentiation
has not yet been fully elucidated, possibly because its for-
mation in the CNS is transient, at least for the amounts
contributed by the high affinity type 2 isozyme, and is prob-
ably limited to some specific CNS structures. It is conceivable
that testosterone acts as differentiating agent via estrogens in
some brain areas, nuclei, or even single neurons and via the
formation of DHT in others.
The low expression observed for 5a-R type 2 in the whole
brain of adult animals apparently contrasts with the expres-
sion of this isoform in early postnatal life, indicating that this
isozyme in adulthood may be expressed in a few localized
brain areas; preliminary data obtained in our laboratory have
indicated that in adult rats, 5a-R type 2 is selectively ex-
pressed in the hypothalamus; after acute stress, this isoform
also appears to be induced in the hippocampus. Therefore,
the action of 5a-R type 2 might be crucial for the local in-
tracerebral formation of active anxiolytic/anesthetic steroids,
FIG. 6. Control of gene expression of the two isoforms of 5a-R in
cultured hypothalamic neurons. Total RNA derived from cultured
control and testosterone- or TPA-treated hypothalamic neurons were
analyzed with RT-PCR/Southern analysis using oligoprimers specific
for type 1 5a-R (upper panel) and type 2 5a-R (lower panel).
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which originate from the 3a-hydroxylation of 5a-reduced de-
rivatives of progesterone and some corticoids (30) that might be
involved in modulating stress responses by their interaction
with the g-aminobutyric acidA receptor complex (6, 31). At time
of birth, when the 5a-R type 2 isoform is highly expressed in the
brain of fetuses, plasma levels of progesterone are extremely
high, providing the substrate for the production of 5a-reduced,
3a-hydroxylated anesthetic compounds, such as tetrahydro-
progesterone [also found more concentrated in the brain (see
Ref. 6 for details) at the time of parturition]; these two factors
(maximal 5a-R type 2 expression and progesterone levels) may
be responsible for attenuating the stress of parturition in new-
born animals. Again, the increased levels of 5a-R type 2 might
be responsible for the sedative state that is occasionally present
in the female during pregnancy (6), providing a possible mo-
lecular explanation for those phenomena. Conversely, the de-
crease in the formation of 5a-reduced metabolites that occurs
postpartum and at the end of the luteal phase of the menstrual
cycle may contribute to the symptoms of postpartum depres-
sion and the premenstrual syndrome (32–34).
With regard to 5a-R type 1, this isozyme is constantly
present at all stages of development. These data combined
with the observation that 5a-R type 1 actively metabolizes
androgens, progesterone, and the corticoids only when they
reach high concentrations inside the cells (because of the low
affinity for the substrates, which is in the micromolar range)
(13) lead us to hypothesize that this isoform might play
essentially a catabolic function, protecting neurons from the
excess of harmful levels of steroid hormones. It is indeed
known that corticoids are potent mediators of several apo-
ptotic processes occurring on selected neurons of the hip-
pocampus (7, 8, 23, 35). Moreover, in the rat brain, 5a-R type
1 is expressed in oligodendrocytes (19), and the enzymatic
protein is highly concentrated in the myelin membranes of
axons (17, 18) formed by these cells. It is well known that
myelin sheaths help protect neurons from toxic insults, reg-
ulating the types and amounts of substances reaching the
axons; 5a-R type 1 may thus work as a component of the
myelin filter. Finally, another protective role for 5a-R type 1
has been recently demonstrated in transgenic mice carrying
a mutated inactive form of 5a-R type 1 (36, 37). These animals
have a smaller litter size due to a higher fetal mortality
during gestation caused by an excess estradiol levels, derived
from increased testosterone bioavailability for aromatase,
not removed by 5a-reduction (37).
The 5a-R isozymes may then play different key regulatory
roles in the CNS, on one side by controlling several specific
brain functions and on the other side by participating in the
catabolism of high concentrations of potentially neurotoxic
steroids.
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